WeVote
Log In

Bill

Bill

H 4950

An Act relative to insulin access

194th Legislature (2025-2026) Introduced by Vanna Howard and 6 co-sponsors

Massachusetts legislation to improve insulin access for diabetic patients, advancing through committees focused on affordability and healthcare financing mechanisms.

Reporting date extended to Thursday, December 31, 2026
0
WeVote Research Nonpartisan
Bill Summary · H 4950

Legislative bill overview

H 4950 seeks to improve insulin access in Massachusetts, though the specific provisions are not detailed in the provided information. Based on the bill's title and committee referrals, it likely addresses affordability, coverage, or distribution mechanisms for insulin. The bill has advanced through the Financial Services Committee and is now under review by the Health Care Financing Committee.

Why is this important

Insulin is a life-sustaining medication for diabetics, yet high costs have created genuine access barriers for many patients. Massachusetts policymakers are increasingly focused on prescription drug affordability, making this legislation part of a broader effort to address healthcare costs. The outcome could affect tens of thousands of state residents managing diabetes.

Potential points of contention

  • Cost-shifting concerns: Industry groups may argue that price controls or coverage mandates shift costs to insurers or employers rather than addressing root causes
  • Scope of coverage: Disagreement may arise over whether the bill covers all insulin types, all patient populations, or includes copay caps versus full coverage
  • Implementation feasibility: Questions about whether Massachusetts can independently regulate insulin pricing without federal coordination or if it duplicates existing federal efforts

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.